{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-005063","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.188623+00:00","generated_at":"2026-06-12T00:37:12.840306+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Harvard Bioscience Q2 revenue $28.8M; adj. op. income up to $3.6M; guides FY23 $116-120M","bullets":["Q2 revenue $28.8M (-1% YoY) as discontinued product headwinds ($1.6M) offset new product growth.","GAAP op. income $0.8M (prior year included $4.9M litigation reversal); adj. op. income rose to $3.6M from $3.1M.","Net loss $1.0M ($0.02 loss/share) vs. net income $2.4M; adjusted EPS $0.04 vs. $0.05.","H1 cash from ops $5.4M; net debt reduced $5.4M YTD to $37.8M.","FY2023 guidance: revenue $116-120M, gross margin ~60%, adj. EBITDA margin 15-17%, net leverage ~2x."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-005063","json":"https://secwatch.observer/filing/0001171843-23-005063.json","markdown":"https://secwatch.observer/filing/0001171843-23-005063.md","text":"https://secwatch.observer/filing/0001171843-23-005063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184323005063/0001171843-23-005063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184323005063/f8k_080823.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T00:37:12.840306+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}